The seventh triMS.online conference
BTK inhibitors: an exciting new era in MS therapy
Took place on Thursday 25 May 2023
triMS.online would like to acknowledge that this event is supported by an Independent Medical Educational Grant from Sanofi and sponsorship provided by Novartis.
13:30 |
Exhibit HallCongress and exhibit hall openFree time to explore the exhibition stands and poster hall |
14:00 |
WelcomeJiwon Oh, Canada (Chair) |
14:10 |
Sanofi Meet the expert sessionThe role of microglia in MS and other neurodegenerative diseasesHeinz Wiendl, Germany |
14:30 |
Q&AHeinz Wiendl, Germany Jiwon Oh, Canada |
14:40 |
What is BTK inhibition?Jacqueline Nicholas, USA |
14:50 |
BTK inhibition - a potential therapeutic target in MSMartin Weber, Germany |
15:00 |
Q&AJacqueline Nicholas, USA Martin Weber, Germany Jiwon Oh, Canada |
15:10 |
Sanofi Meet the expert sessionSubtle MS disease worsening and its underlying biologyBenjamin Greenberg, USA |
15:30 |
Q&ABenjamin Greenberg, USA Jiwon Oh, Canada |
15:40 |
Break
|
16:00 |
Prospects of BTK inhibitors for long-term administration in MSKottil Rammohan, USA Not available on demand |
16:15 |
Q&AKottil Rammohan, USA Jiwon Oh, Canada |
16:20 |
Clinical development of BTK inhibitors in MS - what do we know so farKarolina Piasecka-Stryczynska, Poland |
16:35 |
Learnings from other autoimmune diseases - a safety perspectiveMohammad Sahraian, Iran |
16:50 |
Q&AKarolina Piasecka-Stryczynska, Poland Mohammad Sahraian, Iran Jiwon Oh, Canada |
17:00 |
Positioning of BTK inhibitors in the MS treatment landscapeFrauke Zipp, Germany |
17:15 |
Q&AFrauke Zipp, Germany Jiwon Oh, Canada |
17:25 |
CloseJiwon Oh, Canada (chair) |
triMS.online would like to acknowledge that this event is supported by an Independent Medical Educational Grant from Sanofi and a sponsorship provided by Novartis